Biologic Response Modifiers
Key Points
- Biologic response modifiers (biologics) are drugs derived from living organisms that target specific molecules involved in autoimmune or cancer processes.
- TNF-α inhibitors (adalimumab, etanercept, infliximab) are the most common biologics for RA, Crohn’s disease, and psoriasis.
- Latent TB screening (tuberculin test or IGRA) is mandatory before starting biologic therapy — biologics can reactivate latent tuberculosis.
- Biologics markedly increase infection risk; live vaccines are contraindicated during treatment.
- Hypersensitivity reactions during IV infusion can be life-threatening — premedication and emergency equipment must be available.
Mechanism Overview
Biologics are engineered proteins (monoclonal antibodies, fusion proteins, or receptor constructs) that bind to and neutralize specific cytokines, receptors, or cell surface markers involved in disease processes:
Autoimmune Biologics
| Drug (Brand) | Target | Class | Indications |
|---|---|---|---|
| Adalimumab (Humira) | TNF-α | Anti-TNF monoclonal antibody | RA, psoriatic arthritis, Crohn’s disease, UC, ankylosing spondylitis |
| Etanercept (Enbrel) | TNF-α and TNF-β | Soluble TNF receptor fusion protein | RA, psoriatic arthritis, psoriasis, ankylosing spondylitis |
| Infliximab (Remicade) | TNF-α | Anti-TNF chimeric monoclonal antibody | RA, Crohn’s disease, UC, psoriasis, ankylosing spondylitis |
| Tocilizumab (Actemra) | IL-6 receptor | Anti-IL-6R monoclonal antibody | RA (when TNF inhibitors fail) |
| Abatacept (Orencia) | CD80/CD86 on T cells | CTLA-4-Ig fusion protein | RA (T cell co-stimulation blockade) |
| Rituximab (Rituxan) | CD20 on B cells | Anti-CD20 monoclonal antibody | RA (when TNF inhibitors fail); lymphoma; SLE |
Cancer Biologics
| Drug | Target | Class | Indications |
|---|---|---|---|
| Pembrolizumab (Keytruda) | PD-1 on T cells | Anti-PD-1 monoclonal antibody | Melanoma, NSCLC, many cancers |
| Nivolumab (Opdivo) | PD-1 on T cells | Anti-PD-1 monoclonal antibody | Melanoma, lung cancer, renal cell carcinoma |
| Bevacizumab (Avastin) | VEGF | Anti-VEGF monoclonal antibody | Colorectal cancer, lung cancer, glioblastoma |
| Rituximab (Rituxan) | CD20 on B cells | Anti-CD20 | Non-Hodgkin lymphoma, CLL |
Nursing Assessment
NCLEX Focus
Before ANY biologic therapy, screen for latent tuberculosis (TB skin test or IGRA). Biologics suppress TNF-α — a key cytokine controlling TB granuloma integrity — and can cause life-threatening TB reactivation. A positive test requires TB treatment before starting biologic therapy.
- Screen for latent TB — required before all TNF inhibitor initiation.
- Assess for active infection — biologics are contraindicated with active serious infections.
- Review hepatitis B status — HBsAg, anti-HBc (biologics can reactivate chronic HBV).
- Assess for CHF — TNF inhibitors can worsen heart failure (contraindicated in moderate-severe CHF).
- Assess for demyelinating disease history — TNF inhibitors may worsen multiple sclerosis.
- Assess baseline CBC and LFTs.
- Assess immunization status — administer required vaccines before starting biologic therapy.
Nursing Interventions
- Pre-infusion preparation: Have emergency medications available (epinephrine, diphenhydramine, corticosteroids) — anaphylaxis can occur, especially with first infusion.
- Hypersensitivity monitoring during infusion: Monitor vital signs; watch for chills, fever, dyspnea, chest tightness, urticaria; stop infusion if reaction occurs.
- Premedication: Administer diphenhydramine and acetaminophen prior to rituximab and other IV biologics to reduce infusion reaction risk.
- Infection surveillance: Report any fever, cough, wounds, or unusual symptoms immediately; hold biologic therapy with active infection.
- Live vaccine prohibition: Inform patients that live vaccines (MMR, varicella, intranasal flu) are contraindicated during biologic therapy.
- Injection site teaching: Adalimumab and etanercept are self-injected subcutaneously — teach rotation of injection sites, proper storage (refrigerated), and recognition of injection site reactions.
- Skin and lymph node monitoring: Biologics increase melanoma, lymphoma, and non-melanoma skin cancer risk — report new skin lesions promptly.
Latent TB Reactivation Risk
All TNF inhibitors (adalimumab, etanercept, infliximab) carry a BLACK BOX WARNING for reactivation of latent tuberculosis. Testing must be performed BEFORE initiating therapy. Patients who convert TB tests or show active TB symptoms should have therapy held immediately and be evaluated by infectious disease.
Increased Infection and Malignancy Risk
Biologics suppress the immune system and carry BLACK BOX WARNINGS for serious infections (including opportunistic infections such as histoplasmosis, cryptococcosis, and PCP) and for lymphoma and other malignancies.
Pharmacology Summary
| Drug | Route | Administration Notes |
|---|---|---|
| Adalimumab (Humira) | Subcutaneous injection | Every 2 weeks; self-injectable; refrigerate |
| Etanercept (Enbrel) | Subcutaneous injection | Weekly; self-injectable; refrigerate |
| Infliximab (Remicade) | IV infusion | 0, 2, 6 weeks (induction), then every 8 weeks; premedicate; monitor during infusion |
| Rituximab (Rituxan) | IV infusion | Slow initial rate; increase per protocol; premedicate; risk of tumor lysis syndrome |
| Pembrolizumab (Keytruda) | IV infusion | Every 3 or 6 weeks per protocol |
| Bevacizumab (Avastin) | IV infusion | Every 2–3 weeks; monitor for hypertension, wound healing impairment |
Clinical Judgment Application
Clinical Scenario
A patient with RA is being started on infliximab. During the first infusion at 30 minutes, the patient develops flushing, hives, and reports chest tightness. Blood pressure drops from 122/78 to 94/62.
- Recognize Cues: Acute hypersensitivity reaction (flushing, urticaria, hypotension) during IV biologic infusion.
- Analyze Cues: Anaphylactic reaction to infliximab — a life-threatening emergency.
- Prioritize Hypotheses: Anaphylaxis with hemodynamic compromise is the highest priority.
- Generate Solutions: Stop infusion immediately; administer epinephrine; call rapid response; position supine with legs elevated; prepare IV fluids.
- Take Action: Discontinue infusion, administer epinephrine 0.3 mg IM, notify provider, monitor vitals continuously.
- Evaluate Outcomes: Blood pressure stabilizes, urticaria resolves, respiratory status normalizes after emergency treatment.
Related Concepts
- disease-modifying-antirheumatic-drugs — Conventional DMARDs are tried before biologics in most RA treatment algorithms.
- rheumatoid-arthritis-autoimmune-joint-disease — RA is the primary autoimmune indication for anti-TNF biologics.
- inflammatory-bowel-disease — Infliximab and adalimumab are used in Crohn’s disease and UC treatment.
- active-and-passive-immunity — Understanding immunosuppression mechanisms and vaccine contraindications.
- hypersensitivity-types-and-anaphylaxis-response — Infusion reactions and anaphylaxis management protocols.
Self-Check
- Why must latent tuberculosis be screened and treated before initiating TNF inhibitor therapy?
- What pre-medications are typically given before rituximab infusion, and why?
- What is the mechanism by which PD-1 inhibitors like pembrolizumab treat cancer?